Collaborative Agreements (Details) - USD ($)	6 Months Ended
Jun. 30, 2020	Jun. 30, 2019	Jul. 31, 2020
Collaborative Agreements (Textual)
Cash proceeds from grant received	$ 850,000
Grand award,description	The Company was awarded a $500,000 grant from the Amyotrophic Lateral Sclerosis (ALS) Association to fund a study of the efficacy of XPro1595 to reverse ALS in vitro and to fund a study of the efficacy of XPro1595 to protect against ALS model phenotypes in vivo. During the six months ended June 30, 2020, the Company received $300,000 of cash proceeds pursuant to this grant which the Company recorded as deferred liabilities on the balance sheet as of June 30, 2020.	The Company was awarded a $1,000,000 grant from the Alzheimer’s Association to advance XPro1595, a novel therapy targeting neuroinflammation as a cause of Alzheimer’s disease. The endowment was awarded under the Part the Cloud to RESCUE grant.
Deferred grant	$ 300,000
Grants received	$ 0	$ 600,000
Alzheimer’s Association [Member] \| Subsequent Event [Member]
Collaborative Agreements (Textual)
Final Payment tranche			$ 150,000

The Company was awarded a $500,000 grant from the Amyotrophic Lateral Sclerosis (ALS) Association to fund a study of the efficacy of XPro1595 to reverse ALS in vitro and to fund a study of the efficacy of XPro1595 to protect against ALS model phenotypes in vivo. During the six months ended June 30, 2020, the Company received $300,000 of cash proceeds pursuant to this grant which the Company recorded as deferred liabilities on the balance sheet as of June 30, 2020.

The Company was awarded a $1,000,000 grant from the Alzheimer’s Association to advance XPro1595, a novel therapy targeting neuroinflammation as a cause of Alzheimer’s disease. The endowment was awarded under the Part the Cloud to RESCUE grant.

Grants received

$ 0

$ 600,000

Collaborative Agreements (Textual)